Human V-Set And Immunoglobulin Domain-Containing Protein 4 (VSIG4) Protein
507€ (50 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Human V-Set And Immunoglobulin Domain-Containing Protein 4 (VSIG4) Protein
category
Proteins and Peptides
provider
Abbexa
reference
abx692581
tested applications
SDS-PAGE
Description
Human VSIG4 Protein is a recombinant protein from Human produced in HEK293 Cells. A DNA sequence encoding the human VSIG4 (Q9Y279-1) extracellular domain (Met 1-Pro 283) was expressed, fused with a polyhistidine tag at the C-terminus.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | VSIG4 |
| Host | HEK293 cells |
| Origin | Human |
| Observed MW | Molecular Weight: 30.5 kDa Sequence Fragment: Met1-Pro283 Tag: C-terminal His tag Validity: The validity for this protein is 12 months. |
| Expression | Recombinant |
| Purity | > 96% (SDS-PAGE) |
| Size 1 | 50 µg |
| Size 2 | 100 µg |
| Form | |
| Tested Applications | SDS-PAGE |
| Buffer | Lyophilized from sterile PBS, pH 7.4. |
| Availability | Shipped within 5-15 working days. |
| Storage | Aliquot and store at -20°C or -80°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q9Y279-1 |
| Alias | CRIg,Z39IG,Protein Z39Ig |
| Background | Protein VSIG4 |
| Status | RUO |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Descripción
V-set and immunoglobulin domain containing 4 (VSIG4) is a complement receptor and immune checkpoint protein that primarily functions as an inhibitory molecule in macrophages and antigen-presenting cells. As a negative regulator of T-cell activation, VSIG4 suppresses immune responses by binding to complement components, thereby reducing inflammation and preventing tissue damage in autoimmune and inflammatory conditions. Its immune-inhibitory properties make VSIG4 a potential target for immune modulation therapies, particularly in autoimmune diseases and cancer immunotherapy. In the tumor microenvironment, VSIG4 expression on macrophages is associated with immune evasion, as it inhibits T-cell-mediated anti-tumor responses. Elevated VSIG4 levels have been linked to poor prognosis in several cancers, including hepatocellular carcinoma and melanoma. Beyond its role in immunity, VSIG4 is implicated in metabolic processes, as it interacts with lipid metabolism pathways in macrophages, influencing foam cell formation in atherosclerosis. Therapeutic strategies targeting VSIG4 are being explored to enhance anti-tumor immunity or regulate excessive inflammation, highlighting its significance as a multifunctional immune regulatory molecule.
Related Products
Recombinant Mouse VSIG4
Ver Producto
Recombinant Human VSIG4
Ver Producto